Why Is ARS Pharmaceuticals, Inc. (SPRY) Stock Down -26% Today?
Key Takeaways
- SPRY shares plunged approximately 26% in premarket trading on June 25, 2026, falling from the prior session's close of $10.54 to roughly $7.80
- The primary catalyst was a late Wednesday commercial update confirming no new commercial formulary additions for neffy (epinephrine nasal spray) in the July 1, 2026 payer coverage cycle — a significant miss against market expectations
- The company lowered its full-year 2026 cash-based operating expense guidance to approximately $248 million, signaling tighter spending as insurance coverage expansion stalls
- ARS Pharma reaffirmed its path to cash-flow breakeven in 2027, but investors focused on the absence of a near-term commercial insurance breakthrough that had been widely anticipated
- The selloff represents a sharp single-session reversal; SPRY had gained 2.53% in regular Wednesday trading before the after-hours announcement sent shares tumbling
- Traders are watching payer discussions for the next formulary cycle and interim Phase 2b CSU data expected in Q4 2026
Opening Summary
ARS Pharmaceuticals, Inc. (SPRY) is a Nasdaq-listed biopharmaceutical company commercializing neffy, a needle-free epinephrine nasal spray designed for emergency treatment of severe allergic reactions and anaphylaxis — the first non-injectable alternative to traditional epinephrine auto-injectors in the United States. Shares collapsed approximately 26% in Thursday premarket trading, falling from a prior regular-session close of $10.54 to roughly $7.80, after the company disclosed Wednesday evening that neffy had failed to secure any new major commercial insurance formulary placements in the July 1, 2026 coverage cycle. The announcement dashed investor hopes for a meaningful expansion in payer access that had been expected to underpin revenue acceleration through the second half of 2026.
Failed Formulary Expansion: The Core Catalyst
The central driver behind SPRY's premarket selloff was ARS Pharma's after-hours commercial and financial update released on June 24, 2026. The company stated that, despite payer discussions continuing through mid-June, no new commercial formulary additions or coverage decisions were issued for neffy in the July 1, 2026 cycle. For a company whose entire commercial trajectory is built around expanding insurance coverage for neffy, this was a fundamental near-term growth setback. The market had broadly expected at least one or two major commercial health plan additions in this cycle, making the blank outcome a significant negative surprise.
The company noted that neffy remains accessible to commercially insured patients through a combination of existing direct coverage and a newly introduced retail cash option priced in line with other epinephrine products. However, investors interpreted the cash-pay option — while a viable workaround — as a weaker substitute for broad formulary inclusion, which directly drives prescriptions, physician adoption, and recurring revenue growth. Only Florida's expansion of neffy to its unrestricted Medicaid formulary effective July 1 offered any incremental coverage news, a narrow positive that did little to offset the magnitude of the miss.
Guidance Cut and Financial Outlook
Alongside the coverage update, ARS Pharma reduced its full-year 2026 cash-based operating expense guidance, lowering the forecast to approximately $248 million from prior guidance, reflecting what the company described as "prioritized commercial investment and enhanced cost discipline in the second half of 2026." While cost discipline is generally viewed positively, in this context the reduction signaled that management is pulling back on spending in response to slower-than-expected commercial traction — reinforcing investor concerns that neffy's commercial ramp is losing momentum.
The company reaffirmed its target to reach cash-flow breakeven in 2027, citing continued growth in the neffy base business. CEO Richard Lowenthal emphasized that demand has continued to grow independently of additional coverage additions, noting approximately 120,000 neffy users in the U.S. as of Q1 2026, with nearly 29,500 new patients added in the quarter alone. Nevertheless, Wall Street's reaction reflected skepticism about whether organic demand growth — without major formulary wins — can sustain the pace required to meet 2027 breakeven targets.
Pipeline Context: CSU Program
One forward-looking element of the update offered a potential silver lining. ARS Pharma confirmed that its Phase 2b clinical trial evaluating neffy's intranasal technology for acute flares in chronic spontaneous urticaria (CSU) has completed enrollment of its interim population, with interim data readout expected in Q4 2026. The company views the CSU indication — which affects an estimated 1.6 million patients in the U.S. — as a significant future growth driver. However, binary clinical data events represent both opportunity and risk, and the CSU readout remains months away, providing little near-term relief for investors reacting to the formulary disappointment.
Market Context and Trading Activity
SPRY's premarket plunge was sharply divergent from broader equity market behavior, with S&P 500 futures pointing slightly higher and the Nasdaq showing modest gains — confirming the selloff was entirely company-specific. Trading volume in the premarket session was running substantially above SPRY's daily average of approximately 1.68 million shares, consistent with a high-impact binary catalyst event. The after-hours announcement on Wednesday had already driven shares down more than 23% before Thursday's premarket session extended losses further. From a technical standpoint, the premarket decline pushed SPRY well below its 50-day and 200-day moving averages, breaching multiple support levels and placing the stock near the lower end of its 52-week range of $6.66–$18.89. The small-cap biopharma sector more broadly showed mixed action, with SPRY's peers in the allergy and specialty pharma space not experiencing similar pressure, underscoring that this was a name-specific event rather than sector contagion.
Trending AI Robots
For traders navigating high-volatility events like the one impacting SPRY, Tickeron's Trending AI Robots page provides a curated selection of the platform's top-performing AI trading bots under current market conditions. Tickeron runs hundreds of AI-powered bots covering thousands of tickers across a wide range of strategies — from momentum and breakout trading to mean reversion and swing approaches — with varying timeframes and risk profiles. Only bots demonstrating the strongest performance metrics in the prevailing environment earn a place on the Trending list, offering traders a focused, data-driven starting point. Each bot is transparent about its traded symbols, historical accuracy rates, and strategy parameters. Traders and investors looking for systematic, AI-assisted tools to manage volatility and identify opportunities may find it worth exploring.
What Comes Next for SPRY
The most critical near-term watch item for SPRY is whether ARS Pharma can secure meaningful commercial formulary additions in future payer coverage cycles beyond July 1, 2026. Management has indicated it will continue payer discussions, and any announcements of major health plan wins could serve as a significant positive catalyst. The Q4 2026 interim data readout from the Phase 2b CSU trial represents another pivotal event — a positive signal could meaningfully broaden the investment thesis, while a miss would add to near-term pressure. On the financial side, the company's ability to demonstrate accelerating neffy prescription growth without large new formulary additions will be closely tracked in upcoming quarterly reports. Q1 2026 results had already revealed an EPS miss, and investors will look for Q2 2026 figures to show whether the base business is growing fast enough to support the 2027 breakeven commitment. Broader risks include continued insurance access challenges, competitive dynamics in the epinephrine delivery market, ongoing cash burn, and the inherent uncertainty of Phase 2b clinical outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SPRY's RSI Oscillator recovers from oversold territory
The RSI Oscillator for SPRY moved out of oversold territory on August 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SPRY just turned positive on August 07, 2026. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where SPRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SPRY entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (43.668) is normal, around the industry mean (20.145). SPRY's P/E Ratio (151.250) is considerably higher than the industry average of (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.666) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement